Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264446 | 0.84 | BACE1 (0.63) | BACE1LTA4HMAPK14CCR5LMNA | |
| SCHEMBL14007526 | 0.79 | BACE1 (0.69) | BACE1LTA4HMAPK14LMNAALDH1A1 | |
| SCHEMBL8264459 | 0.79 | BACE1 (0.66) | BACE1LTA4HMAPK14LMNAALDH1A1 | |
| SCHEMBL5215584 | 0.77 | LTA4H (0.45) | LTA4HMAPK14MRGPRX1MRGPRX4 | |
| SCHEMBL8264955 | 0.75 | BACE1 (1.00) | BACE1LTA4HMAPK14CCR5MRGPRX1 | |
| SCHEMBL14007515 | 0.74 | MEN1 (0.53) | BACE1CCR5ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20147117 | 0.74 | MRGPRX4 (0.53) | CCR5LMNAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL8265027 | 0.73 | BACE1 (0.52) | BACE1LTA4HMAPK14CCR5LMNA | |
| SCHEMBL769497 | 0.72 | RXRA (0.50) | CCR5LMNAMAOBALDH1A1RAB9A | |
| SCHEMBL768907 | 0.72 | MRGPRX4 (0.52) | CCR5LMNAMAOBHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | BACE1 30/4885LTA4H 1470/4885MAPK14 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.